BIOMAT Database Logo BIOMAT Database Logo

Effects of the 5-HT3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity. 1990

G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Department of Psychiatry, University of Vienna, Austria.

1. The selective 5-HT3 receptor antagonist, ICS 205-930 (Sandoz), has been reported to have potent effects on gastric smooth muscle in vivo and to enhance gastric emptying in animals and in man. 2. This study investigated the effects of ICS 205-930 on fat-delayed gastric emptying of a semisolid meal and antral motor activity in humans. 3. Twelve healthy men participated in each of three studies in which 10 or 20 mg of ICS 205-930 or placebo were infused i.v. in a random double-blind fashion. Gastric emptying and antral motor activity were studied scintigraphically. 4. Gastric emptying was not altered after 10 mg but slower after 20 mg of ICS 205-930 than after placebo. Emptying after 20 mg of ICS 205-930 was significantly slower than after 10 mg of ICS 205-930. 5. Antral contraction amplitude was slightly lower after 20 mg of ICS 205-930 than after placebo, whereas the effects of 10 mg ICS 205-930 did not differ from those of placebo. 6. The results suggest that the investigated doses of ICS 205-930 have only slight effects on gastric motor activity of healthy young men, with 20 mg reducing the rate of emptying.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D011706 Pyloric Antrum The region between the sharp indentation at the lower third of the STOMACH (incisura angularis) and the junction of the PYLORUS with the DUODENUM. Pyloric antral glands contain mucus-secreting cells and gastrin-secreting endocrine cells (G CELLS). Antrum, Pyloric,Gastric Antrum,Antrum, Gastric,Antrums, Gastric,Antrums, Pyloric,Gastric Antrums,Pyloric Antrums
D004041 Dietary Fats Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados. Fats, Dietary,Dietary Fat,Fat, Dietary
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005746 Gastric Emptying The evacuation of food from the stomach into the duodenum. Emptying, Gastric,Emptyings, Gastric,Gastric Emptyings
D005769 Gastrointestinal Motility The motor activity of the GASTROINTESTINAL TRACT. Intestinal Motility,Gastrointestinal Motilities,Intestinal Motilities,Motilities, Gastrointestinal,Motilities, Intestinal,Motility, Gastrointestinal,Motility, Intestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077526 Tropisetron An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting. (3 alpha-Tropanyl)-1H-indole-3-carboxylic Acid Ester,ICS 205-930,ICS-205-930,ICS-205930,Indole-3-carboxylic Acid Tropine Ester,Navoban,Tropisetron Hydrochloride,ICS 205 930,ICS 205930,Indole 3 carboxylic Acid Tropine Ester
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
5-HT3 antagonist ICS 205-930 enhances naltrexone's effects on ethanol intake.
May 2004, European journal of pharmacology,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects.
September 1988, Gut,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Similar effects of diazepam and the 5-HT3 receptor antagonist ICS 205-930 on place aversion conditioning.
July 1988, European journal of pharmacology,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Effects of the 5-HT3 antagonist ICS 205-930 on benzodiazepine withdrawal signs in rats.
February 1992, Behavioural pharmacology,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
January 1989, The Journal of pharmacology and experimental therapeutics,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men.
September 1989, British journal of clinical pharmacology,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Effects of the 5-HT3 receptor antagonist, ICS 205-930, on oesophageal motor activity and on lower oesophageal sphincter pressure: a double-blind cross-over study.
December 1990, Hepato-gastroenterology,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Inhibition of cholera toxin-induced intestinal secretion by the 5-HT3 receptor antagonist ICS 205-930.
June 1989, Naunyn-Schmiedeberg's archives of pharmacology,
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.
May 1987, Lancet (London, England),
G Stacher, and H Bergmann, and C Schneider, and G Steiner-Mittelbach, and G Gaupmann, and H Steinringer, and T A Abatzi, and G Stacher-Janotta
Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930.
March 1989, Naunyn-Schmiedeberg's archives of pharmacology,
Copied contents to your clipboard!